PI-RADS 4 病例分析:针对穿刺阴性患者的管理建议
这项前瞻性单中心横断面研究纳入 931 例 3 T 多参数 MRI 后接受靶向联合系统穿刺的病例,分析其中 193 例 PI-RADS 4 病灶。总体前列腺癌检出率 62%(119/193),临床显著前列腺癌 48%(92/193);外周带无干扰征象的明确 PI-RADS 4 病灶前列腺癌检出率 95%(临床显著 73%),而移行带伴间质增生叠加征象的 PI-RADS 4 病灶仅 11%(临床显著 4%)。作者建议对明确的(外周带)PI-RADS 4 病灶行靶向再穿刺,移行带伴间质增生叠加征象者或可优先复查 MRI。
要点
- 外周带无前列腺炎干扰征象的明确 PI-RADS 4 病灶前列腺癌检出率 95%,临床显著癌 73%。
- 移行带 PI-RADS 4 病灶伴间质增生叠加征象时前列腺癌仅 11%,临床显著癌 4%。
- 靶向穿刺针芯漏诊临床显著癌索引病灶见于 7% 的患者。
核心结论
- 经验丰富的阅片者用多参数 MRI 可可靠检出小的临床显著前列腺癌,但单纯靶向 MR/US 融合穿刺可能漏诊;作者建议对明确的(外周带)PI-RADS 4 病灶行靶向再穿刺,而移行带伴间质增生叠加征象的 PI-RADS 4 病灶或可优先复查 MRI 随访。
研究设计与样本
- 前瞻性、经 IRB 批准的单中心横断面研究,连续纳入 931 例因前列腺癌检测行 3 T 多参数 MRI 的患者,其中 193 例 PI-RADS 4 并接受靶向 MRI/US 融合引导联合系统 12 针 TRUS 引导穿刺作为参考标准后纳入分析。
关键影像表现/征象
- 外周带无额外干扰性前列腺炎征象的明确 PI-RADS 4 索引病灶前列腺癌检出率 95%,临床显著癌 73%。
- 移行带 PI-RADS 4 病灶伴间质增生叠加征象时前列腺癌检出率 11%,临床显著癌 4%。
- 靶向穿刺针芯漏诊临床显著癌索引病灶见于 7% 的患者。
诊断标准与关键数值
- 全部 193 例 PI-RADS 4 患者中前列腺癌 119 例(62%),临床显著前列腺癌(Gleason 评分 ≥3+4=7)92 例(48%)。
- 前列腺癌患者前列腺特异抗原密度(PSAD)显著更高。
临床应用与阅片要点
- 作者建议对明确的(外周带)PI-RADS 4 病灶行靶向再穿刺。
- 作者认为移行带伴间质增生叠加征象的 PI-RADS 4 病灶或可优先复查 MRI 随访。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate if subgroups of patients assigned to MRI category PI-RADS 4 regarding clinical and MRI imaging aspects have distinct risks of prostate cancer (PCa) to facilitate adequate clinical management of this population, especially after negative targeted biopsy.
METHODS: This prospective, IRB approved single center cross-sectional study includes 931 consecutive patients after mp-MRI at 3 T for PCa detection. 193 patients with PI-RADS assessment category 4 received subsequent combined targeted MRI/US fusion-guided and systematic 12-core TRUS-guided biopsy as reference standard and were finally analyzed. The primary endpoint was PCa detection of PI-RADS 4 with MRI subgroup analyses. Secondary endpoints were analyses of clinical data, location of PCa, and detection of targeted biopsy cores.
RESULTS: PCa was detected in 119 of 193 patients (62%) including clinically significant PCa (csPCa; Gleason score ≥3 + 4 = 7) in 92 patients (48%). MRI subgroup analysis revealed 95% PCa (73% csPCa) in unambiguous PI-RADS 4 index lesions without additional, interfering signs of prostatitis in the peripheral zone or overlaying signs of severe stromal hyperplasia in the transition zone according to PI-RADS v2. Transition zone confined PI-RADS-4-lesions with overlaying signs of stromal hyperplasia showed PCa only in 11% (4% csPCa). Targeted biopsy cores missed the csPCa index lesion in 7% of the patients. PSA density (PSAD) was significantly higher in PCa patients.
CONCLUSIONS: Small csPCa can reliably be detected with mp-MRI by experienced readers, but can be missed by targeted MR/US fusion biopsy alone. Targeted re-biopsy of unambiguous (peripheral) PI-RADS-4-lesions is recommended; whereas transition zone confined PI-RADS-4-lesions with overlaying signs of stromal hyperplasia might be followed-up by re-MRI primarily.
引用
- Ullrich T, Arsov C, Quentin M, et al. Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients. Eur J Radiol. 2019. PMID: 30927932. doi:10.1016/j.ejrad.2019.01.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。